Intellia Therapeutics (NTLA) Misses Q4 EPS by 1c, Revenues Beat

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.94 million versus the consensus estimate of $9.94 million.

“In 2019, we advanced our full-spectrum strategy, guiding both our in vivo and ex vivo lead programs toward the clinic. We also continued to build on our genome editing and delivery capabilities to enable a rapid succession of candidates,” said Intellia President and Chief Executive Officer, John Leonard, M.D. “We are off to a productive start in 2020. We announced the nomination of NTLA-5001, a WT1-directed TCR-T cell therapy for the treatment of AML, and plan to select our third development candidate in the first half of this year, which will be for the treatment of HAE. In addition, in the second half of the year, we expect to begin dosing ATTR patients with NTLA-2001, a potential single-course treatment for ATTR patients. This is anticipated to be the first-ever systemically delivered CRISPR/Cas9-based therapy to enter the clinic, representing an important milestone in our mission to deliver potentially curative therapies from our proprietary modular platform.”

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Premier Financial (PFC) Tops Q1 EPS by 3c
• Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance